Ocrevus Denied by Insurance?
How to Appeal & Get Approved
Generic: ocrelizumab
The first FDA-approved treatment for primary progressive MS — with relatively fewer PA barriers.
- Used for
- MS
- Route
- IV
- Specialty
- Neurology
- PA Required
- Yes — 85% of prescriptions
Common Denial Reasons
Ocrevus is frequently denied for step therapy, documentation, and formulary reasons. Decode your specific denial →
require prior authorization before your pharmacy can fill them. If you've been denied, you're not alone — and most denials can be overturned on appeal.
Step Therapy Requirements
"Fail first" — what insurers require before approving Ocrevus
Most insurers require you to try alternative medications before approving Ocrevus. See your insurer's requirements →
Let Ellen Fight Your Ocrevus Denial
Ellen generates a personalized appeal letter for Ocrevus using your denial reason, insurer, and clinical situation.
- ✓Instant denial decoding — understand why you were denied
- ✓Payer-specific appeal language that matches your insurer's criteria
- ✓Clinical evidence suggestions your doctor can use
Insurance Coverage
Ellen tracks Ocrevus coverage across 35+ major insurers including formulary status, step therapy requirements, and common denial patterns.
Check your insurer's Ocrevuspolicy →Safety Information
From FDA-approved prescribing information for Ocrevus (Anti-CD20 Monoclonal Antibody)
Hepatitis B virus reactivation, progressive multifocal leukoencephalopathy (PML)
Do Not Use If
- ✕Active hepatitis B virus infection
- ✕History of life-threatening infusion reaction to ocrelizumab
Key Warnings
- ⚠Screen for hepatitis B before starting
- ⚠Infusion reactions common — premedicate with corticosteroid + antihistamine
- ⚠May increase risk of malignancies including breast cancer
- ⚠Vaccinate at least 6 weeks before starting (live vaccines contraindicated during treatment)
This is not a complete list. See the full Ocrevus prescribing information or ask your pharmacist for comprehensive safety data.
Frequently Asked Questions
›Does Ocrevus require step therapy?
Unlike many other specialty drugs, Ocrevus typically does not require step therapy. Most major insurers approve it as first-line treatment for relapsing MS and primary progressive MS, as long as a neurologist prescribes it.
›Why was my Ocrevus denied?
Common denial reasons include: prescription not from a neurologist, concurrent use with another MS disease-modifying therapy, or missing documentation for continuation (disease stability must be demonstrated).
›Is the subcutaneous Ocrevus Zunovo covered?
Ocrevus Zunovo (SC formulation) is newer and coverage varies. Some plans still require the IV formulation. If you prefer the SC version, your neurologist may need to document why (e.g., poor IV access, infusion reaction history).